|
Gene Information
|
Gene Name
|
NR3C2 |
|
Gene ID
|
4306
|
|
Gene Full Name
|
nuclear receptor subfamily 3 group C member 2 |
|
Gene Alias
|
MR; MCR; MLR; NR3C2VIT |
|
Transcripts
|
ENSG00000151623
|
|
Virus
|
HBV |
|
Gene Type
|
protein coding |
|
HPA Location Info
|
Nucleoplasm;
|
|
HPA Protein Class Info
|
Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors |
|
Uniport_ID
|
P08235
|
|
HGNC ID
|
HGNC:7979
|
|
VEGA ID
|
OTTHUMG00000161455
|
|
OMIM ID
|
600983 |
|
String ID
|
9606.ENSP00000350815
|
|
Drugbank ID
|
BE0000668
|
|
Drug (Cytoscape Annotation)
|
Dexamethasone |
|
PharmGKB ID
|
PA242
|
Target gene [NR3C2] related to VISs
Relationship between gene expression and immune infiltrating cell level
| Data ID |
Disease |
Sample number |
Sample type |
|
LIHC (TCGA) |
Liver hepatocellular carcinoma |
424 |
Liver hepatocellular carcinoma HCV (HBV+)(86), Liver hepatocellular carcinoma HCV (HBV-)(19), Liver hepatocellular carcinoma (HBV+)(209), Liver hepatocellular carcinoma (HBV+)(60), Paracancerous HCV (HBV+)(4), Paracancerous (HBV-)(28), Paracancerous (HBV+)(18) |
> Dataset: LIHC
|
|
HeatMap of cell type fractions in all samples
|
Lollipop of NR3C2 expression and immune infiltrating cell level correlation result in HBV+ samples
|
NR3C2 expression: Low -> High
|
|
|
|
|